Metformin Sr Crescent Pharma

Metformin, the active ingredient in Metformin Sr Crescent Pharma, is a Biguanide presented as an unknown/unknown for oral use. It treats type 2 diabetes mellitus in adults by improving blood glucose control.

GNH USA supplies Metformin Sr Crescent Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metformin is indicated for conditions involving impaired glucose regulation and is used primarily in the management of type 2 diabetes.

Type 2 diabetes mellitus: improves glycemic control and reduces HbA1c levels. Prediabetes (impaired glucose tolerance): delays progression to overt diabetes. Polycystic ovary syndrome (off‑label): helps restore ovulatory cycles and reduces insulin resistance.

Metformin is generally well tolerated, but several adverse reactions have been reported.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, and loss of appetite. - Diarrhea: frequent loose stools, especially during treatment initiation. - Metallic taste: transient alteration in taste perception. - Flatulence: increased intestinal gas. - Weight loss: modest reduction in body weight. - Vitamin B12 deficiency: decreased absorption with long‑term use.

Serious or Rare Side Effects: - Lactic acidosis: rare but potentially fatal metabolic acidosis. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Hypoglycemia: when combined with insulin or sulfonylureas. - Acute pancreatitis: infrequent inflammatory pancreatic episodes. - Anemia: due to reduced red‑cell production in rare cases.

Metformin should be used with careful clinical monitoring and patient education. - Renal function assessment: evaluate creatinine clearance before initiation and periodically. - Hepatic function monitoring: avoid use in severe liver disease. - Contraindicated in severe renal impairment: do not use if eGFR <30 mL/min/1.73 m². - Risk of lactic acidosis: discontinue before radiologic contrast studies. - Use with caution in elderly patients: start at lower doses and monitor tolerance. - Store at ambient temperature: keep in the original container, protect from moisture and heat.

Metformin may interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Iodinated contrast agents: increase risk of lactic acidosis; withhold metformin before and after imaging. - Cimetidine: may raise metformin plasma concentrations. - Alcohol: potentiates lactic acidosis, especially in patients with hepatic disease.

Moderate Interactions (Monitor Closely): - Thiazide diuretics: can impair renal function, raising metformin levels. - Beta‑blockers: may mask hypoglycemia symptoms. - ACE inhibitors or ARBs: monitor renal function and electrolytes. - NSAIDs: may reduce renal clearance of metformin. - Certain antiretrovirals (e.g., protease inhibitors): may increase metformin exposure.